公开(公告)号：WO2020223538A8

公开(公告)日：2020-11-05

申请号：PCT/US2020/030819

申请日：2020-04-30

Applicant: CALICO LIFE SCIENCES LLC ,  ABBVIE INC.

Inventor： MARTIN, Kathleen, Ann ,  SIDRAUSKI, Carmela ,  SHI, Lei ,  MURAUSKI, Kathleen, J. ,  XU, Xiangdong ,  TONG, Yunsong ,  RANDOLPH, John, T. ,  DART, Michael, J. ,  BENELKEBIR, Hanae ,  EDESON, Steven ,  STARBUCK, Kathryn

IPC: C07D311/74 ,  A61P25/00 ,  A61P35/00 ,  A61P37/00 ,  C07C1/00 ,  C07D213/53 ,  C07D265/36 ,  C07D271/10 ,  C07D405/06 ,  C07D405/12 ,  C07D405/14 ,  C07D407/12 ,  C07D413/04 ,  C07D413/12 ,  C07D417/12 ,  A61K31/165 ,  A61K31/353 ,  A61K31/397 ,  A61K31/4025 ,  A61K31/403 ,  A61K31/4155 ,  A61K31/422 ,  A61K31/4245 ,  A61K31/437 ,  A61K31/4433 ,  A61K45/06 ,  A61P25/28 ,  C07C235/22 ,  C07C235/36 ,  C07C235/40 ,  C07C2601/04 ,  C07C2602/38 ,  C07C2602/44 ,  C07D311/22 ,  C07D311/24 ,  C07D471/04 ,  C07D471/08 ,  C07D493/08

Abstract: Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases, disorders and conditions.

公开(公告)号：WO2023018990A2

公开(公告)日：2023-02-16

申请号：PCT/US2022/040256

申请日：2022-08-12

Applicant: LIFE TECHNOLOGIES CORPORATION

Inventor： BOUDIF, Arezki ,  GEBEHEYU, Gulilat ,  JESSEE, Joel ,  BRASSARD, Christopher J. ,  VEROVSKAYA, Evgenia ,  PARAYATH, Neha

IPC: C07D295/125 ,  A61K9/127 ,  C07C225/20 ,  A61K48/00 ,  A61K48/0041 ,  A61K9/1272 ,  A61K9/5123 ,  C07C2601/04 ,  C12N15/88

Abstract: New lipids are provided that are useful for delivering macromolecules, such as nucleic acids, into eukaryotic cells and tissue. The lipids can be used alone, in combination with other lipids and/or in combination with other transfection enhancing reagents to prepare transfection complexes and complexes for in vivo delivery of bioactive agents.

公开(公告)号：WO2021076938A8

公开(公告)日：2021-04-22

申请号：PCT/US2020/056048

申请日：2020-10-16

Applicant: AMBYS MEDICINES, INC.

Inventor： CHAO, Jianhua ,  HOLLENBACH, Stanley J. ,  HOLMES, Michael Christopher ,  MATJE, Douglas M. ,  SNEAD, Nicholas M. ,  BERGNES, Gustave ,  MELLEM, Kevin T. ,  MORGANS, David John, Jr.

IPC: C07C49/242 ,  C07D311/94 ,  C07D311/02 ,  A61K31/122 ,  C07C2601/02 ,  C07C2601/04 ,  C07C2601/08 ,  C07C2601/18 ,  C07C2602/18 ,  C07C2602/50 ,  C07C321/22 ,  C07C49/717 ,  C07C49/753 ,  C07D211/32 ,  C07D305/06 ,  C07D307/12 ,  C07D307/93 ,  C07D309/06 ,  C07D333/22 ,  C07D493/08

Abstract: Disclosed are a series of compounds or their tautomers having a general structure represented by Formula (la), (lb), (Ila), (lIb), or (lIc) and pharmaceutically acceptable salts thereof. The present disclosure also relates to pharmaceutical compositions comprising said compounds or tautomers. The present disclosure further relates to a method of treating a disease or condition associated with iron dysregulation or dysfunctional iron homeostasis comprising administering to a subject in need thereof a therapeutically effective amount of Formula (la), (lb), (Ila), (lIb), or (lIc) compounds or tautomers.

公开(公告)号：WO2022000868A1

公开(公告)日：2022-01-06

申请号：PCT/CN2020/122298

申请日：2020-10-21

Applicant: 上海皓元生物医药科技有限公司

Inventor： 张宏伟 ,  张大明 ,  马涛 ,  朱琦伟 ,  周治国 ,  梅魁 ,  郑保富 ,  高强 ,  袁海玲

IPC: C07C233/25 ,  C07C233/33 ,  C07C231/12 ,  C07D491/16 ,  C07D491/22 ,  C07C231/02 ,  C07C2601/04 ,  C07C2602/10

Abstract: 提供了一种用于合成喜树碱衍生物的中间体及其制备方法和用途。中间体A可由3-氟-4-甲基苯胺经过酰化、溴代、交叉偶联反应得到。该中间体A可以用于制备中间体B进而制备伊喜替康甲磺酸盐。中间体化合物B可由中间体A经过重排反应得到；伊喜替康甲磺酸盐可由化合物B经过ɑ位上乙酰氨基、氨基脱保护、缩合反应、水解反应得到。所述反应起始物价格低廉，各步反应条件温和，操作简便，收率高，适合工业化生产。

公开(公告)号：WO2021226276A2

公开(公告)日：2021-11-11

申请号：PCT/US2021/030950

申请日：2021-05-05

Applicant: CYTOKINETICS, INC.

Inventor： ROMERO, Antonio ,  CHANDRA, Aroop ,  EVANS, Christopher ,  SHEN, Minxing

IPC: C07D401/12 ,  C07D213/40 ,  C07D211/98 ,  C07D231/12 ,  C07D263/32 ,  C07D413/12 ,  C07D221/20 ,  C07D213/38 ,  C07D205/12 ,  C07D207/06 ,  C07D205/04 ,  C07D401/04 ,  C07D295/192 ,  C07D215/08 ,  C07D217/06 ,  A61P25/00 ,  A61P29/00 ,  A61P3/00 ,  A61P35/00 ,  C07B2200/07 ,  C07C2601/04 ,  C07C2601/08 ,  C07C2601/14 ,  C07C2602/24 ,  C07C2602/28 ,  C07C2603/94 ,  C07C275/24 ,  C07C275/26 ,  C07C317/28 ,  C07C317/30 ,  C07D209/08 ,  C07D209/44 ,  C07D209/54 ,  C07D211/94 ,  C07D213/50 ,  C07D213/71 ,  C07D213/81 ,  C07D213/82 ,  C07D215/12 ,  C07D215/18 ,  C07D215/20 ,  C07D231/56 ,  C07D241/04 ,  C07D265/36 ,  C07D295/185 ,  C07D305/08 ,  C07D307/22 ,  C07D309/08 ,  C07D335/02 ,  C07D401/06 ,  C07D403/04 ,  C07D403/10 ,  C07D403/12 ,  C07D405/06 ,  C07D413/06 ,  C07D471/04

Abstract: Provided are compounds of Formula (II): or a pharmaceutically acceptable salt thereof, wherein R1, n, and Y1 are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (II), or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula (II), or a pharmaceutically acceptable salt thereof.

公开(公告)号：WO2021124272A1

公开(公告)日：2021-06-24

申请号：PCT/IB2020/062218

申请日：2020-12-18

Applicant: LIMINAL BIOSCIENCES LIMITED

Inventor： GAGNON, Lyne ,  LEBLOND, François ,  GEERTS, Lilianne ,  ZACHARIE, Boulos ,  DOYLE, Chris ,  MARTEL, Julien ,  DUCEPPE, Jean-Simon ,  LACOSTE, Jean-Eric ,  THIBODEAU, Jean-François

IPC: A61P3/04 ,  A61P3/10 ,  A61P7/06 ,  A61P9/12 ,  A61P35/00 ,  C07C53/134 ,  C07C57/26 ,  C07D303/12 ,  C07B2200/05 ,  C07C2601/02 ,  C07C2601/04 ,  C07C2601/14 ,  C07C2602/44 ,  C07C53/23 ,  C07C61/04 ,  C07C61/16

Abstract: The present application discloses a compound of formula (I) or a salt thereof: (I) and compositions comprising such compound or salt thereof. The use of such compound, salt thereof or composition comprising same for treating anemia or leukopenia, fibrosis, cancer, hypertension and/or a metabolic condition in a subject is also disclosed.

公开(公告)号：WO2022264037A1

公开(公告)日：2022-12-22

申请号：PCT/IB2022/055513

申请日：2022-06-14

Applicant: INTRABIO LTD.

Inventor： CHURCHILL, Grant Charles

IPC: C07C233/47 ,  C07C233/52 ,  A61K31/22 ,  A61P25/00 ,  C07B2200/07 ,  C07C2601/02 ,  C07C2601/04

Abstract: The present disclosure provides compounds represented by Formula I: I, and the pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, and R3 are as defined as set forth in the specification. The present disclosure also provides compounds having Formula I for use to treat or prevent the progression of a lysosomal storage disorder or a neurodegenerative disease in a subject, provide neuroprotection in a subject having a lysosomal storage disorder, treat or prevent a migraine, and the symptoms associated therewith, in a subject, or improve mobility and/or cognitive function in a subject.

公开(公告)号：WO2022038365A2

公开(公告)日：2022-02-24

申请号：PCT/GB2021/052158

申请日：2021-08-20

Applicant: SITRYX THERAPEUTICS LIMITED

Inventor： COOKE, Michael Liam ,  FYFE, Matthew Colin Thor ,  TEOBALD, Barry John

IPC: C07C69/60 ,  C07D257/04 ,  A61P29/00 ,  A61P37/00 ,  A61K31/225 ,  A61K31/41 ,  C07D213/30 ,  C07D305/08 ,  C07D331/04 ,  C07D213/61 ,  C07D309/10 ,  C07D333/16 ,  C07D239/26 ,  A61K31/351 ,  A61K31/337 ,  A61K31/38 ,  A61K31/381 ,  A61K31/505 ,  C07C2601/04 ,  C07C2601/14 ,  C07C2601/18 ,  C07C2602/50 ,  C07C2603/18 ,  C07C69/73

Abstract: The invention relates to compounds of formula (I) and to their use in treating or preventing an inflammatory disease or a disease associated with an undesirable immune response: wherein R, R1, R2 and RB are as defined herein.

公开(公告)号：WO2022152109A2

公开(公告)日：2022-07-21

申请号：PCT/CN2022/071251

申请日：2022-01-11

Applicant: SUZHOU ABOGEN BIOSCIENCES CO., LTD.

Inventor： YING, Bo ,  WANG, Xiulian

IPC: C07C217/08 ,  C07F9/24 ,  A61K9/127 ,  A61K9/51 ,  A61K31/7105 ,  A61K47/18 ,  C07C219/06 ,  C07C219/14 ,  C07C229/24 ,  C07C229/30 ,  C07C233/36 ,  C07C237/06 ,  C07C271/12 ,  C07C271/20 ,  C07C211/58 ,  C07F9/22 ,  C07C229/14 ,  C07D211/58 ,  A61K9/1272 ,  A61K9/5123 ,  C07C2601/02 ,  C07C2601/04 ,  C07C2601/08 ,  C07C2601/14 ,  C07C2601/18 ,  C07D309/14 ,  C07D319/06 ,  C07F9/2458

Abstract: Provided herein are lipid compounds that can be used in combination with other lipid components, such as neutral lipids, cholesterol and polymer conjugated lipids, to form lipid nanoparticles for delivery of therapeutic agents (e.g., nucleic acid molecules) for therapeutic or prophylactic purposes, including vaccination. Also provided herein are lipid nanoparticle compositions comprising said lipid compounds.

公开(公告)号：WO2021260090A1

公开(公告)日：2021-12-30

申请号：PCT/EP2021/067288

申请日：2021-06-24

Applicant: IDORSIA PHARMACEUTICALS LTD

Inventor： BEZENCON, Olivier ,  DEYMIER, Caroline ,  PETERS, Jens-Uwe ,  SIEGRIST, Romain ,  SURIVET, Jean-Philippe

IPC: C07C275/26 ,  C07D213/64 ,  C07D239/34 ,  A61P25/00 ,  C07C2601/04

Abstract: The invention relates to compounds of Formula (I) wherein X1, X2, X3, L, RX4, R1, R2A, R2B, R3, R4, R5, and R6 are as described in the description; to their preparation, to pharmaceutically acceptable salts thereof, to pharmaceutical compositions containing one or more compounds of Formula (I), and to the use of such compounds as medicaments, especially as Kv7 openers.